Roche's experimental oral drug for breast cancer giredestrant could enter a market worth at least 10 billion Swiss francs ...
Jazz Pharmaceuticals’ Zepzelca, once on the brink of a market withdrawal, has returned with new trial results showing it ...
Roche's experimental oral drug for breast cancer giredestrant could enter a market worth at least 10 billion Swiss francs ...
As Roche comes under competitive pressure on its breast cancer business, the Swiss company hopes a new drug will add a ...
Brian Roche – when the consultant becomes the bossHaving begun his public sector career as one of those highly paid ...
Roche (RHHBY) has received FDA approval for its drug Itovebi in combination with two other drugs for the treatment of breast ...
Novartis' Piqray/Vijoice (alpelisib) is the only PIK3CA inhibitor to have reached the market for breast cancer, having been ...
Skin care aficionados everywhere are making space for a dermatologist-backed, budget-friendly brand in their medicine ...
The US FDA approved Itovebi in combination with Pfizer’s Ibrance and AstraZeneca’s Faslodex for certain breast cancer ...
With the regulatory approval for advanced breast cancer, Roche’s inavolisib is a potential challenger to Novartis’ PI3K ...
Some trails in the park in central Wisconsin reopened Friday to hikers days after a fire damaged stairway that leads to the ...
Footballer Stephanie Roche has admitted it was “an emotional day” when she hung up her football boots for the final time. On ...